Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00689221 · ClinicalTrials.gov registry record · Phase 3
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status
A Phase 3 study of Glioblastoma, sponsored by EMD Serono.
- Completed
- Registry status
- Phase 3
- Development phase
- 545
- Enrollment target
- 2
- Study locations
NCT00689221: Completed Phase 3 study of Glioblastoma, sponsored by EMD Serono.
NCT00689221 is a Phase 3 study of Glioblastoma that has completed, run by EMD Serono. The registered enrollment target is 545 participants, above the 106-participant average among 199 other Glioblastoma trials with a reported enrollment target (414% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00689221, a Phase 3 study of Glioblastoma, has completed, sponsored by EMD Serono.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 545 participants
- Enrollment target
- 2
- Study locations
Study Summary
CENTRIC is a Phase 3 clinical trial assessing efficacy and safety of the investigational integrin inhibitor, cilengitide, in combination with standard treatment versus standard treatment alone in newly diagnosed glioblastoma subjects with a methylated O6-methylguanine-deoxyribonucleic acid methyltransferase (MGMT) gene promoter in the tumor tissue. The MGMT gene promoter is a section of deoxyribonucleic acid (DNA) that acts as a controlling element in the expression of MGMT. Methylation of the MGMT gene promoter has been found to be a predictive marker for benefit from temozolomide (TMZ) treatment.
Primary Outcome
The OS time is defined as the time (in months) from randomization to death or last day known to be alive. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.
Conditions Studied
Interventions
- DRUG Temozolomide
- RADIATION Radiotherapy
- DRUG Cilengitide
Study Locations (2)
Massachusetts
- Please Contact U.S. Medical Information Located in - Rockland
Other
- Please Contact the Merck KGaA Communication Center Located in - Darmstadt
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 545 participants |
| Start Date | 2008-09 |
| Est. Completion | 2013-08 |
| Phase | Phase 3 |
What the finished NCT00689221 record still lists
NCT00689221 is an interventional study that assigns participants to a tested intervention. The registered 545 participants enrollment target is mid-sized for trials with a published cap, above the 106-participant average among 199 other Glioblastoma trials with a reported enrollment target (414% higher).
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 3 interventions - of which Temozolomide is the first listed.
NCT00689221 reports a single indexed study location in Massachusetts, Other.
Frequently Asked Questions
What is clinical trial NCT00689221 about?
NCT00689221 is a clinical study titled "Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status". CENTRIC is a Phase 3 clinical trial assessing efficacy and safety of the investigational integrin inhibitor, cilengitide, in combination with standard treatment versus standard treatment alone in newly diagnosed glioblastoma subjects with a methylated O6-methylguanine-deoxyribonucleic acid methyltra...
What is the current status of trial NCT00689221?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 545 participants. The study started on 2008-09. Estimated completion is 2013-08.
What conditions does trial NCT00689221 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT00689221?
The interventions under investigation include: Temozolomide (DRUG), Radiotherapy (RADIATION), Cilengitide (DRUG).
Who is sponsoring clinical trial NCT00689221?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00689221 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00689221's enrollment target sits among peer trials
545 10th of 199 higher than 190 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
RECRUITING · Phase 3
-
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
RECRUITING · Phase 3
-
Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients
RECRUITING · Phase 3
-
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
RECRUITING · Phase 3
-
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
RECRUITING · Phase 3
-
Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04553523 · 545 participants · NA
Hydrus® Microstent New Enrollment Post-Approval Study
- NCT03572374 · 546 participants · NA
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job
- NCT05937685 · 546 participants · NA
Reducing Blood Pressure in Patients With High Cardiovascular Risk
- NCT06416150 · 546 participants · NA
Reducing Urban Cervical Cancer Disparities
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia